Search Result

Isoforms Recommended:	CA Ⅱ CA

Results for "

hCA II

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Antibiotic (1) Apoptosis (10) Bacterial (3) Calcium Channel (1) Carbonic Anhydrase (105) CDK (3) Cholinesterase (ChE) (11) Dipeptidyl Peptidase (1) DNA/RNA Synthesis (1) Endogenous Metabolite (3) Fungal (1) Glycosidase (2) HDAC (1) HSV (1) Interleukin Related (1) Isotope-Labeled Compounds (3) JNK (1) mTOR (3) NKCC (3) NOD-like Receptor (NLR) (2) P-glycoprotein (1) p38 MAPK (1) Phosphodiesterase (PDE) (1) Reactive Oxygen Species (ROS) (2) Reference Standards (4) Sodium Channel (1) VEGFR (3) Wnt (1) β-catenin (1) β-glucuronidase (2)
By Research Areas:	Cancer (50) Cardiovascular Disease (3) Endocrinology (3) Infection (10) Inflammation/Immunology (9) Metabolic Disease (14) Neurological Disease (35)
Click Chemistry:	Azide (1)

111

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: GPR109A Photosystem II CD74

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-118467

Benzolamide 2 Publications Verification CL11366	Carbonic Anhydrase	Neurological Disease Cancer
Benzolamide (CL11366) is a potent carbonic anhydrase (CA) inhibitor, with K_is of 15 nM, 9 nM, 94 nM and 78 nM for hCA I, hCA II, EcoCAγ and VchCAγ, respectively. Benzolamide also inhibits CAS3, with a K_i of 54 nM. Benzolamide can be used for the research of glaucoma and seizures .

HY-W074975

CL 5343 5-Amino-1,3,4-thiadiazole-2-sulfonamide	Carbonic Anhydrase	Cancer
CL 5343 (5-Amino-1,3,4-thiadiazole-2-sulfonamide) is a selective inhibitor of carbonic anhydrase B (HCA-B) and isoforms I, II, IV, and VII. CL 5343 has a K_i of 7.9 nM for hCA II. CL 5343 acts as a CA9 ligand to achieve targeted delivery of maytansine to the cell membrane of SKRC52 renal cancer cells. CL 5343 is useful in the development of therapeutics for diseases associated with CA overactivity, such as glaucoma, epilepsy, and cancer .

HY-163109

Carbonic anhydrase inhibitor 16	Carbonic Anhydrase	Infection
Carbonic anhydrase inhibitor 16 (compound 1) is a dengue protease inhibitor with inhibitory activity against carbonic anhydrase hCA I and hCA II (K_i: 28.5 nM, 2.2 nM) .

HY-69085

4-Bromo-1H-indazole	Carbonic Anhydrase	Others
4-Bromo-1H-indazole is a carbonic anhydrase inhibitor, with an IC₅₀ of 0.403 mM and a K_i of 0.383 mM against hCA-I, as well as an IC₅₀ of 0.700 mM and a K_i of 0.935 mM against hCA-II. 4-Bromo-1H-indazole reduces the catalytic activity of human I and II isoforms of carbonic anhydrase .

HY-W008343

1,3-Dimethyluracil	Endogenous Metabolite	Metabolic Disease
1,3-Dimethyluracil is a pyrimidone derives from a uracil. 1,3-Dimethyluracil found occasionally in human urine. 1,3-Dimethyluracil shows inhibition activity against hCA I and hCA II (human carbonic anhydrase) with K_i of 316.2 μM and 166.4 μM, respectively .

HY-W012168

4-Chloro-3-sulfamoylbenzoic acid	Carbonic Anhydrase	Metabolic Disease
4-Chloro-3-sulfamoylbenzoic acid is a weak inhibitor of human carbonic anhydrase isoforms hCA I, hCA II, hCA IV, and hCA IX, and a synthesis intermediate for carbonic anhydrase inhibitors. 4-Chloro-3-sulfamoylbenzoic acid is the major metabolite of tripamide detected in tissues, urine, and feces of rats and rabbits following Tripamide (HY-106570) administration. 4-Chloro-3-sulfamoylbenzoic acid can be used for the study of carbonic anhydrase inhibition and species differences in drug metabolism .

HY-178017

*BChE/hCA* II-IN-1**	Cholinesterase (ChE) Carbonic Anhydrase	Neurological Disease
BChE/hCA II-IN-1 (Compound 20) is a dual-functional inhibitor of Butyrylcholinesterase (BChE) and human carbonic anhydrase II (hCA II) with IC₅₀s of 76.50 and 10.69  μM for BChE and hCA II, respectively. BChE/hCA II-IN-1 can be used for neurodegenerative diseases like Alzheimer's and glaucoma research .

HY-175847

hCA-I/hCA-II-IN-2	Carbonic Anhydrase	Cancer
hCA-I/ HCA-II-IN-2 (compound 5 k) is an effective inhibitor of human carbonic anhydrase I (hCA-I) and II (hCA-II). The IC₅₀ for hCA I and hCA II are 89.25 and 54.50 nM respectively .

HY-146206

HCAIX-IN-1	Carbonic Anhydrase	Cancer
HCAIX-IN-1 (compound 21e) is a potent and selective HCAIX inhibitor with K_Is of 694.9, 126.6, 3.3, 9.8 nM for hCA I, hCA II, hCA IX, hCA XII, respectively .

HY-147986

hCA I-IN-2	Carbonic Anhydrase	Cancer
hCA I-IN-2 (Compound 6d) is a selective *human carbonic anhydrase I (hCA* I) inhibitor with K_i** values of 18.8, 375.1, 1721 and 283.9 nM against hCA I, hCA II, hCAIX and hCAXII, respectively .

HY-147985

hCA I-IN-1	Carbonic Anhydrase	Cancer
hCA I-IN-1 (Compound 6q) is a *human carbonic anhydrase I (hCA* I) inhibitor with K_i** values of 38.3, 716.4, 940.1 and 192.8 nM against hCA I, hCA II, hCAIX and hCAXII, respectively .

HY-155391

hCA/Wnt/β-catenin-IN-1	Carbonic Anhydrase P-glycoprotein Wnt β-catenin	Cancer
hCA/Wnt/β-catenin-IN-1 (Compd 15) is an inhibitor of *hCA* (K_i: 33.6, 24.1, 6.8 nM for hCA II, hCA IX, hCA XII). hCA/Wnt/β-catenin-IN-1 reduces P-gp activity. hCA/Wnt/β-catenin-IN-1 also inhibits Wnt/β-catenin signaling pathway. hCA/Wnt/β-catenin-IN-1 inhibits cancer cell viability, including the NCI/ADR-RES DOX-resistant cell line .

HY-152140

hCAII-IN-8	Carbonic Anhydrase	Cancer
hCAII-IN-8, an amide, is a highly selective carbonic anhydrase (CA) inhibitor with an IC₅₀ value of 0.18 μM against hCA II .

HY-B1471

Fluorometholone acetate 1 Publications Verification	Carbonic Anhydrase	Inflammation/Immunology
Fluorometholone acetate is a synthetic glucocorticoid corticosteroid and a corticosteroid ester. Fluorometholone acetate potently inhibits carbonic anhydrase (CA) with IC₅₀s of 2.18 μM and 17.5 μM for *hCA-I* and *hCA-II*, respectively. Fluorometholone acetate has anti-inflammatory effect and has the potential for external ocular inflammation research .

HY-B0124S

Zonisamide-d4	Isotope-Labeled Compounds Carbonic Anhydrase Calcium Channel Sodium Channel	Neurological Disease
Zonisamide-d₄ is the deuterium labeled Zonisamide. Zonisamide (AD 810) is an inhibitor of zinc enzyme carbonic anhydrase (CA), with K_is of 35.2 nM and 20.6 nM for human mitochondrial isozyme hCA II and hCA V, respectively. Zonisamide has antiepileptic activity. Zonisamide can be used for the rsearch for epilepsy, seizures and Parkinson's disease .

HY-150973

hCAII-IN-4	Carbonic Anhydrase β-glucuronidase	Neurological Disease Metabolic Disease Cancer
hCAII-IN-4 (Compound 12j) is a potent hCA II inhibitor with an IC₅₀ of 7.78 μM. hCAII-IN-4 also inhibits β-glucuronidase with an IC₅₀ of 773.9 μM .

HY-B0124A

Zonisamide sodium AD 810 sodium; CI 912 sodium	Carbonic Anhydrase Apoptosis	Cardiovascular Disease Neurological Disease
Zonisamide (AD 810) sodium is an orally active carbonic anhydrase inhibitor, with K_is of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide sodium exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide sodium also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide sodium can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .

HY-138365

EMAC10101d	Carbonic Anhydrase	Others
EMAC10101d is a potent and selective toward hCA II inhibitor, with a K_i of 8.1 nM .

HY-174835

hCA-I/hCA-II-IN-1	Carbonic Anhydrase	Cardiovascular Disease
hCA-I/hCA-II-IN-1 (Compound P4) is a potent dual human carbonic anhydrase I (hCA-I) and human carbonic anhydrase II (hCA-II) inhibitor with K_i values of 0.22 μM and 0.33 μM, respectively. hCA-I/hCA-II-IN-1 can be used in research on diseases related to CA enzymes such as glaucoma, hypertension, and ulcers .

HY-178922

CAI/II-IN-13	Carbonic Anhydrase	Cancer
CAI/II-IN-13 (Compound 5f) is a *CAI/II* inhibitor, with IC₅₀ values of 309.16 nM for hCA I and 267.27 nM for hCA II. CAI/II-IN-13 exhibits potent and selective antiproliferative activity against A549 lung cancer cells (IC₅₀ = 0.58 μM). CAI/II-IN-13 can be used for the study of lung cancer .

HY-W031519

Chloraminophenamide	Carbonic Anhydrase	Cardiovascular Disease
Chloraminophenamide (Compound 14) is a carbonic anhydrase inhibitor, with *K_is of 75, 160 and 8400 nM for hCA* II, bCA IV and hCA I, respectively. Chloraminophenamide has the potential for antiglaucoma research .**

HY-147799

hCA XII/II/IX-IN-1	Carbonic Anhydrase	Cancer
hCA XII/II/IX-IN-1 (Compound 3) is a potent human carbonic anhydrase (hCA) inhibitor with IC₅₀ values of 2.6, 0.004, 0.005 and 0.001 μM against hCA I, hCA II, hCA IX and hCA XII, respectively. hCA XII/II/IX-IN-1 shows anticancer activity .

HY-150570

Carbonic anhydrase inhibitor 14	Carbonic Anhydrase CDK	Cancer
Carbonic anhydrase inhibitor 14 (Compound 8b) is a carbonic anhydrase (CA) inhibitor with K_i values of 1203, 99.7, 9.4 and 27.7 nM against hCA I, hCA II, hCA IX and hCA XII, respectively. Carbonic anhydrase inhibitor 14 can also inhibit CDK2 with an IC₅₀ of 20.3 μM. Carbonic anhydrase inhibitor 14 shows antitumor activity .

HY-101136

Dealanylascamycin AT-265	Antibiotic Carbonic Anhydrase Bacterial	Infection
Dealanylascamycin (AT-265) (Compound 2) is a nucleoside antibiotic. AT 265 is a carbonic anhydrase (CA) inhibitor, with K_i values of 167, 65.2, 234, and 143 nM for hCA I, hCA II, hCA IV, and hCA IX respectively. Dealanylascamycin is the active form of Ascamycin (HY-121071). Dealanylascamycin exhibits broad-spectrum antibacterial activity and is effective against pathogenic bacteria such as Xanthomonas citri (MIC = 0.4 μg/mL). Dealanylascamycin has high cytotoxicity .

HY-179271

CA/HDAC-IN-1	Carbonic Anhydrase HDAC	Cancer
CA/HDAC-IN-1 (Compound 11) is a CA and HDAC inhibitor with K_i values of 7.4 nM, 31.0 nM, and 7.3 nM for hCA II, hCA IX, and hCA XII, respectively, and IC₅₀ values of 0.21 μM and 3.60 μM for HDAC3 and HDAC8, respectively. CA/HDAC-IN-1 has anti-cancer activity against colon cancer, breast cancer, and melanoma .

HY-149012

*AChE/hCA* I/II-IN-1**	Cholinesterase (ChE) Carbonic Anhydrase	Neurological Disease Endocrinology
AChE/hCA I/II-IN-1 (Compound 6) is a potent inhibitor of *AChE/Hca* with IC₅₀ values of 22.21, 60.79 and 66.64 nM for AChE, Hca Ⅰ and Hca Ⅱ. AChE/hCA I/II-IN-1 can be used for the rsearch for glaucoma, Alzheimer's disease, diabetes .

HY-32933

4-Acetylphenylboronic acid	Carbonic Anhydrase	Metabolic Disease
4-Acetylphenylboronic acid is a potent inhibitor of carbonic anhydrases II(CA II), with IC₅₀s of 246 μM and 281.40 μM for bovine CA II (bCA II) and human CA II (hCA II). 4-Acetylphenylboronic acid can be obtained via mechanochemistry and solvent evaporation. 4-Acetylphenylboronic acid has a loss of the carbonyl group at 500-550 K .

HY-172103

hCAI/II-IN-10	Carbonic Anhydrase	Others
hCAI/II-IN-10 (Compound 5d) is a human carbonic anhydrase I and II (hCA I and hCA II) inhibitor with IC₅₀ values are 4.32 and 3.89 nM respectively .

HY-144641

Carbonic anhydrase inhibitor 7	Carbonic Anhydrase	Cancer
Carbonic anhydrase inhibitor 7 (compound 5b) is a potent inhibitor of human carbonic anhydrase (hCA), with K_is of 6.5 nM, 7.1 nM, 72.1 nM, and 255.8 nM for hCA IX, hCA II, hCA XII and hCA I, respectively .

HY-144640

Carbonic anhydrase inhibitor 6	Carbonic Anhydrase	Cancer
Carbonic anhydrase inhibitor 6 (compound 9b) is a potent inhibitor of human carbonic anhydrase (hCA), with K_is of 9.7 nM, 35.2 nM, 88.5 nM, and 91.8 nM for hCA IX, hCA II, hCA XII and hCA I, respectively .

HY-178362

CAII/VII-IN-1	Carbonic Anhydrase NKCC mTOR	Neurological Disease
CAII/VII-IN-1 is an orally active hCA II (K_I = 12.3 nM), and hCA VII (K_I = 22.6 nM) inhibitor, showing no significant activity against hCA I. CAII/VII-IN-1 shows excellent neuroprotective activity in vivo Pilocarpine (HY-B0726A)-induced seizure model. CAII/VII-IN-1 can upregulate KCC2 and inhibit mTOR, exerting neuroprotective effects. CAII/VII-IN-1 does not show any significant neurotoxic effects or alterations in liver and kidney function. CAII/VII-IN-1 can be used for the study of epilepsy .

HY-162063

hCAIX/XII-IN-9	Carbonic Anhydrase	Inflammation/Immunology Cancer
hCAIX/XII-IN-9 (compound 8) is a potent carbonic anhydrase (CA) inhibitor with K_i values of 1658 nM, 184.8 nM, 8.9 nM, 64.8 nM for hCA I, hCA II, hCA IX, and hCA XII, respectively .

HY-163268

Carbonic anhydrase inhibitor 18	Carbonic Anhydrase	Cancer
Carbonic anhydrase inhibitor 18 (Compound 9) is a human carbonic anhydrase (hCA) isoform inhibitor, with K_is of 604.8, 333.6, 1.9 and 6.7 nM for hCA I, hCA II, hCA IX and hCA XII, respectively. Carbonic anhydrase inhibitor 18 can be used for the research of cancer .

HY-156169

hCAIX/XII-IN-7	Carbonic Anhydrase	Cancer
hCAIX/XII-IN-7 (compound 3e) is a potent hCA IX and XII inhibitor with K_is of 3.2 nM, 9.2 nM, 503.7 nM and 59 nM for hCA I, hCA II, hCA IX and hCA XII, respectively. hCAIX/XII-IN-7 has the potential for hypoxic tumors research .

HY-172607

Carbonic anhydrase inhibitor 30	Carbonic Anhydrase	Infection
Carbonic anhydrase inhibitor 30 (compound 17) is an inhibitor of carbonic anhydrase with K_i values of 2.13 μM and 0.161 nM for hCA I and hCA II, respectively ^{[1] ^.}

HY-150572

CDK2-IN-11	CDK Carbonic Anhydrase	Cancer
CDK2-IN-11 (compound 9d) is a potent CDK2 inhibitor with an IC₅₀ of 6.4 μM, and K_I values of 23.4 nM, 56.3 nM and 44.3 nM for hCA II, hCA IX and hCA XII, respectively. CDK2-IN-11 can be used for researching anticancer .

HY-161142

Carbonic anhydrase/AChE-IN-1	Carbonic Anhydrase Cholinesterase (ChE)	Neurological Disease
Carbonic anhydrase/AChE-IN-1 (compound 16) is a carbonic anhydrase and AChE inhibitor with K_is of 24.42 nM, 19.95 nM, and 5.07 nM for hCA I, hCA II, and AChE, respectively .

HY-151578

*DPP IV/hCA* II-IN-1**	Dipeptidyl Peptidase Carbonic Anhydrase	Metabolic Disease
DPP IV/hCA II-IN-1 is a potent and selective dipeptidyl peptidase IV (DPP IV) and carbonic anhydrase (CA) inhibitor with an IC₅₀ value of 0.049 μM for DPP IV and with K_i values of 0.0361, 0.0428, 0.0941, 0.1328, 0.2615, and 3.034 μM for CA II, CA VB, CA VA, CA IX, CA I, and CA IV, respectively .

HY-146979

*hA2A/hCA* XII modulator 1**	Adenosine Receptor Carbonic Anhydrase	Cancer
hA2A/hCA XII modulator 1 (compound 14), a triazolopirazine, is a potent hA_2A adenosine receptor (hA_2AAR) antagonist with K_is of 6.4 nM, 4.819 μM, >30 μM for hA_2AAR, hA₁AR, hA₃AR, respectively. hA2A/hCA XII modulator 1 is a potent *human carbonic anhydrase XII (hCA* XII) inhibitor with K_i*s of 6.2 nM, 46 nM, 466 nM, 8.351 μM for hCA* XII, hCA II, hCA IX and hCA I, respectively. hA2A/hCA XII modulator 1 has the potential for cancer research .

HY-W008343R

1,3-Dimethyluracil (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease
1,3-Dimethyluracil is a pyrimidone derives from a uracil. 1,3-Dimethyluracil found occasionally in human urine. 1,3-Dimethyluracil shows inhibition activity against hCA I and hCA II (human carbonic anhydrase) with Ki of 316.2 μM and 166.4 μM, respectively .

HY-151472

hCAIX/XII-IN-6	Carbonic Anhydrase	Infection
hCAIX/XII-IN-6 is an orally active carbonic anhydrase (CA) inhibitor. hCAIX/XII-IN-6 inhibits human CA isoforms hCA I, II, IV, IX, and XII with K_i values of 6697 nM, 2950 nM, 4093 nM, 4.1 nM and 7.7 nM, respectively. hCAIX/XII-IN-6 can be used for the research of rheumatoid arthritis (RA) .

HY-148135

hCAI/II-IN-6	Carbonic Anhydrase	Neurological Disease
hCAI/II-IN-6 is an orally active human carbonic anhydrase (CA) inhibitor. hCAI/II-IN-6 selectively inhibits hCA II and hCA VII isoforms with K_i values of 220, 4.9, 6.5 and ＞50000 nM for hCA I, hCA II , hCA VII and hCA XII respectively. hCAI/II-IN-6 shows anticonvulsant activity and anti maximal electroshock (MES) activity in vivo. hCAI/II-IN-6 can be used for the research of epilepsy .

HY-146385

hCAI/II-IN-1	Carbonic Anhydrase	Cancer
hCAI/II-IN-1 (Compound 3h) is a human carbonic anhydrase I and II (hCA *I/II) inhibitor with IC₅₀* values of 0.047 µM and 0.024 µM against hCA I and hCA II, respectively .

HY-147922

hCAI/II-IN-2	Carbonic Anhydrase	Inflammation/Immunology
hCAI/II-IN-2 (compound 2b) is a potent dual **hCA I/II** inhibitor with K_i values of 40.97, 15.15 and 61.88 nM for hCA I, hCA II and hCA Ⅸ. hCAI/II-IN-2 possesses anti-hypoxic activity against acute mountain sickness (AMS) and low cellular activity .

HY-147923

hCAI/II-IN-3	Carbonic Anhydrase	Inflammation/Immunology
hCAI/II-IN-3 (compound 5b) is a potent dual **hCA I/II** inhibitor with K_i values of 51.25, 13.15 and 42.18 nM for hCA I, hCA II and hCA Ⅸ. hCAI/II-IN-3 possesses anti-hypoxic activity against acute mountain sickness (AMS) and low cellular activity .

HY-147925

hCAI/II-IN-4	Carbonic Anhydrase	Others
hCAI/II-IN-4 (compound 6d) is a potent dual **hCA I/II** inhibitor with K_i values of 16.95, 15.22 and 27.04 nM for hCA I, hCA II and hCA Ⅸ, respectively. hCAI/II-IN-4 has anti-hypoxia activities and low toxicity. hCAI/II-IN-4 can be used for acute mountain sickness (AMS) research .

HY-161507

hCAI/II-IN-8	Carbonic Anhydrase Cholinesterase (ChE)	Metabolic Disease
hCAI/II-IN-8 (Compound 8) is a hydrazide derivative based on 4-hydroxybenzaldehyde. hCAI/II-IN-8 primarily targets human carbonic anhydrase isomerase I (hCA I) and II (hCA II) for inhibition (IC₅₀ = 21.35 ± 0.39 nM (hCA I); 7.12 ± 0.12 nM (hCA II)). hCAI/II-IN-8 inhibits AChE and BChE as well(IC₅₀ = 46.27 ±0.75 nM (AChE); 43.38 ± 0.83 nM (BChE)). . .

HY-146007

hCAIX-IN-17	Carbonic Anhydrase	Cancer
hCA IX-IN-1 (Compound 6f) is a human carbonic anhydrase (hCA) inhibitor with K_i values of 331.4, 28.4, 9.4 and 17.8 nM against hCA I, hCA II, hCA IX and hCA XII, respectively. hCA IX-IN-1 shows anticancer activity .

HY-146355

hCAII-IN-2	Carbonic Anhydrase	Cancer
hCAII-IN-2 (Compound 11f) is a cytosolic human carbonic anhydrase (hCA) inhibitor with K_i values of 261.4, 3.8, 19.6 and 45.2 nM against hCA I, hCA II, hCA IX and hCA XII, respectively .

HY-144639

Carbonic anhydrase inhibitor 5	Carbonic Anhydrase	Infection Inflammation/Immunology Cancer
Carbonic anhydrase inhibitor 5 is a potent and selective human carbonic anhydrase (hCA) inhibitor with IC₅₀s of 42.9, 47,6 and 6.7 nM for hCA II, hCA IX and hCA XII, respectively .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W008343

1,3-Dimethyluracil	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
1,3-Dimethyluracil is a pyrimidone derives from a uracil. 1,3-Dimethyluracil found occasionally in human urine. 1,3-Dimethyluracil shows inhibition activity against hCA I and hCA II (human carbonic anhydrase) with K_i of 316.2 μM and 166.4 μM, respectively .

HY-W008343R

1,3-Dimethyluracil (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
1,3-Dimethyluracil is a pyrimidone derives from a uracil. 1,3-Dimethyluracil found occasionally in human urine. 1,3-Dimethyluracil shows inhibition activity against hCA I and hCA II (human carbonic anhydrase) with Ki of 316.2 μM and 166.4 μM, respectively .

HY-N19401

Vescalagin	Structural Classification Phenols Polyphenols Myrciaria dubia (Kunth) McVaugh Myrtaceae Plants Source Classification	Cholinesterase (ChE) Carbonic Anhydrase Glycosidase JNK p38 MAPK
Vescalagin is a hexahydroxyphenol. Vescalagin is isolable from Camu-camu (Myrciaria dubia) and immature wax apple fruits. Vescalagin exhibits inhibitory activity against a variety of enzymes, with a K_i value of 5.87 nM against AChE, 3.89 nM against BChE, 11.75 nM against hCA I, 16.23 nM against hCA II, and 16.08 nM against α-glucosidase. Vescalagin inhibits hCA I, hCA II and α-glucosidase in a non-competitive manner. Vescalagin downregulates JNK/p38 MAPK to protect pancreatic β-cells and improve insulin secretion in methylglyoxal-treated rats. Vescalagin reduces hyperglycemia and hypertriglyceridemia in rats fed a high-fructose diet. Vescalagin possesses anti-inflammatory and antioxidant properties .

Cat. No.	Product Name	Chemical Structure

HY-B0124S

Zonisamide-d4
Zonisamide-d₄ is the deuterium labeled Zonisamide. Zonisamide (AD 810) is an inhibitor of zinc enzyme carbonic anhydrase (CA), with K_is of 35.2 nM and 20.6 nM for human mitochondrial isozyme hCA II and hCA V, respectively. Zonisamide has antiepileptic activity. Zonisamide can be used for the rsearch for epilepsy, seizures and Parkinson's disease .

HY-B0124S2

Zonisamide-13C6

Zonisamide- ¹³C₆ (AD 810- ¹³C₆) is ¹³C labeled Zonisamide. Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with K_is of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .

HY-B0124S3

Zonisamide-15N,d4

Zonisamide- ¹⁵N,d₄ is the ¹⁵N- and deuterium labeled Zonisamide (HY-B0124). Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with K_is of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .

Cat. No.	Product Name		Classification

HY-159128

hCAIX-IN-21		Azide
hCAIX-IN-21 (compound 16c) is a potent hCAIX inhibitor with K_I values of 5.2, 3.5, 12.6, 13600 nM for hCAIX, hCA II, hCA XII, hCA I, respectively. hCAIX-IN-21 inhibits cathepsin B enzyme activity .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks